log in | register
Username
Password
Remember me
Journals
Services
Search
Advanced search
Summary
March 2008, Vol. 17, No. 3, Pages 437-443
(doi:10.1517/13543784.17.3.437)

Alitretinoin: a comprehensive review
Caleb Cheng1, Jason Michaels2 & Noah Scheinfeld3
1Jefferson Medical College, USA
2University of Nevada School of Medicine, USA
3Columbia University, Columbia University School of Medicine, Department of Dermatology, 150 West 55th Street, New York, NY 10019, USA +1 212 991 6490; +1 646 349 2493;
† Author for correspondence



Background: Alitretinoin (9-cis-retinoic acid) is a unique panagonist retinoid, capable of binding to all six known retinoid receptors (RAR-α, -β, -γ, and RXR-α, -β, -γ). Studies are being carried out to determine how best to utilize this characteristic in treatments for conditions such as chronic hand dermatitis. Objective: To review the literature on alitretinoin. Methods: The scope of the review encompasses ways that alitretinoin is currently and may potentially be utilized. Results/conclusions: Orally administered alitretinoin is a safe and effective treatment for chronic hand dermatitis. Topical treatment with alitretinoin can be expanded into other areas such as photoaged skin and cutaneous T-cell lymphoma. Despite these benefits, oral alitretinoin will face a difficult path attaining approval for use in the US.

Full Text PDF (116.909 KB) PDF Plus (179.142 KB)
 

Prev. Article | Next Article
View/Print PDF (117 KB)
View PDF Plus (179 KB)
Add to favourite
Email to a friend
TOC Alert | Citation Alert What is RSS?

Quick Links
 • Alert me when:
New articles cite this article
 • Download to citation manager
 • Related articles found in:
Expert Opinion series
 • View Most Downloaded Articles
 
 
Quick Search
for 
Authors:
Caleb Cheng
Jason Michaels
Noah Scheinfeld
Keywords:
9-cis-retinoic acid
alitretinoin
chronic hand dermatitis
Kaposi's sarcoma
retinoids


Informa Healthcare, Telephone House, 69-77 Paul Street, London, EC2A 4LQ, UK
Tel: +44 (0)20 7017 5000 · Fax: +44 (0)20 7017 7667
We welcome your Feedback. See our Privacy Statement and Terms and Conditions